You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SHR-A1811

Showing 1 - 25 of 944
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor

Not yet recruiting
  • HER2-expressing Advanced Solid Tumors
  • SHR-A1811 combined with Pyrotinib.
  • SHR-A1811 combined with other antitumor therapies
  • (no location specified)
Aug 28, 2023

Gynaecological Malignancies Trial (SHR- A1811)

Not yet recruiting
  • Gynaecological Malignancies
  • SHR- A1811
  • (no location specified)
Jun 8, 2023

HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

Not yet recruiting
  • HER2-PositiveRecurrent or Metastatic Breast Cancer
  • SHR-A1811 Injection
  • +2 more
  • (no location specified)
Sep 21, 2023

HER2 Low Advanced or Metastatic Breast Cancer Trial (SHR-A1811 & Dalpiciclib Isethionate Tablets, SHR-A1811 & Fulvestrant,

Not yet recruiting
  • HER2 Low Advanced or Metastatic Breast Cancer
  • SHR-A1811 & Dalpiciclib Isethionate Tablets
  • +2 more
  • (no location specified)
Mar 19, 2023

Breast Cancer Trial (SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Apr 3, 2023

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811;SHR-1701;capecitabine;oxaliplatin)

Not yet recruiting
  • HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jan 3, 2023

Metastatic Breast Cancer Trial in Zhengzhou (SHR-A1811, Pyrotinib, Bevacizumab)

Not yet recruiting
  • Metastatic Breast Cancer
  • SHR-A1811
  • +2 more
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Mar 13, 2023

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,

Not yet recruiting
  • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
  • SHR-A1811
  • Trastuzumab Emtansine
  • (no location specified)
Nov 7, 2023

Breast Cancer Trial (SHR-A1811 for injection ; capecitabine)

Not yet recruiting
  • Breast Cancer
  • SHR-A1811 for injection ; capecitabine
  • (no location specified)
May 4, 2023

HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

Not yet recruiting
  • HER2 Low Breast Carcinoma
  • SHR-A1811 for injection
  • (no location specified)
Jun 12, 2023

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
  • SHR-A1811
  • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
  • (no location specified)
Nov 6, 2023

HER2-positive Breast Cancer Trial in Shenyang (SHR-A1811, Pyrotinib)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Dec 1, 2022

Advanced NSCLC Trial (SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316)

Not yet recruiting
  • Advanced Non-small Cell Lung Cancer
  • SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
  • (no location specified)
Jul 29, 2022

Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

Not yet recruiting
  • Triple-negative Breast Cancer
  • A1: SHR-A1811
  • +11 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 19, 2023

HER2 Positive Non Resectable or Metastatic Breast Cancer Trial (SHR-A1811:Pyrroltinib, SHR-A1811;Pertuzumab, SHR-A1811;SHR-1316)

Not yet recruiting
  • HER2 Positive Non Resectable or Metastatic Breast Cancer
  • (no location specified)
Apr 25, 2022

Advanced Solid Tumors Trial in Shanghai, Chengdu (SHR-A1811, Fluzoparib Capsule)

Enrolling by invitation
  • Advanced Solid Tumors
  • SHR-A1811
  • Fluzoparib Capsule
  • Shanghai, Shanghai, China
  • +1 more
Jun 28, 2022

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Trial in

Recruiting
  • HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
  • SHR-A1811
  • Pyrotinib in combination with Capecitabine.
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Aug 8, 2022

Advanced Salivary Gland Carcinoma Trial in Shanghai (SHR-A1811, SHR 3680 + leuprolide, SHR-A1921)

Not yet recruiting
  • Advanced Salivary Gland Carcinoma
  • SHR-A1811
  • +2 more
  • Shanghai, China
    Dongmei Ji
Jun 21, 2023

Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)

Active, not recruiting
  • Breast Cancer
  • SHR-A1811
  • TROP2 ADC
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 11, 2023

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Advanced NSCLC Trial in Shanghai (SHR-A1811)

Recruiting
  • Advanced Non-small Cell Lung Cancer
  • SHR-A1811
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Jun 1, 2021

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Advanced Solid Tumors Trial in Worldwide (SHR-A1811)

Recruiting
  • Advanced Solid Tumors
  • SHR-A1811
  • Bronx, New York
  • +33 more
Dec 22, 2021

Healthy Trial (SHR-2001, Placebo)

Not yet recruiting
  • Healthy
  • (no location specified)
Jul 4, 2023

B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • SHR-A1912; R-Chemo
  • (no location specified)
Oct 23, 2023